All patients had to be confirmed as having HER2-positive breast cancer by immunohistochemistry and FISH, had metastatic disease and had progressed while being treated with or within 6 months of taxanes and tratsuzumab. This evidence concerns the gene ERBB2 and breast carcinoma.